Roberts, Glore & Co’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.34M Buy
36,518
+10,370
+40% +$491K 0.37% 67
2025
Q4
$1.33M Sell
26,148
-668
-2% -$34.2K 0.35% 66
2025
Q3
$1.49M Buy
26,816
+6,217
+30% +$364K 0.41% 61
2025
Q2
$1.42M Buy
20,599
+9,510
+86% +$647K 0.42% 61
2025
Q1
$770K Buy
11,089
+7,946
+253% +$656K 0.23% 95
2024
Q4
$270K Sell
3,143
-62
-2% -$6.71K 0.08% 176
2024
Q3
$382K Sell
3,205
-225
-7% -$30K 0.11% 146
2024
Q2
$490K Hold
3,430
0.15% 122
2024
Q1
$440K Sell
3,430
-100
-3% -$11.9K 0.13% 131
2023
Q4
$365K Sell
3,530
-138
-4% -$13.6K 0.11% 137
2023
Q3
$334K Sell
3,668
-122
-3% -$10.7K 0.11% 140
2023
Q2
$307K Buy
3,790
+46
+1% +$3.76K 0.1% 154
2023
Q1
$298K Sell
3,744
-60
-2% -$4.25K 0.1% 151
2022
Q4
$257K Buy
+3,804
New +$223K 0.09% 158
2022
Q3
Sell
-4,004
Closed -$223K 189
2022
Q2
$223K Hold
4,004
0.07% 173
2022
Q1
$222K Sell
4,004
-1,600
-29% -$82.1K 0.06% 190
2021
Q4
$314K Hold
5,604
0.08% 157
2021
Q3
$269K Hold
5,604
0.08% 160
2021
Q2
$235K Buy
+5,604
New +$217K 0.07% 175

Other funds holding NVO

Roberts, Glore & Co's NVO Position: Q1 2026 in Review

Roberts, Glore & Co increased its Novo Nordisk (NVO) stake by 40% in Q1 2026, buying an estimated $491K and bringing the position to 36,518 shares worth $1.34M. The position accounts for 0.37% of the portfolio, ranked #67.

Roberts, Glore & Co first reported a position in NVO in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.49M in Q3 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Roberts, Glore & Co held 36,518 shares of Novo Nordisk worth $1.34M as of Q1 2026.
  • Roberts, Glore & Co bought 10,370 Novo Nordisk shares in Q1 2026, an estimated $491K.
  • Novo Nordisk made up 0.37% of Roberts, Glore & Co's portfolio in Q1 2026, its #67 holding.
  • Roberts, Glore & Co first reported a position in Novo Nordisk in Q2 2021 and has held it in 19 quarters since.
  • Roberts, Glore & Co's Novo Nordisk position peaked at $1.49M in Q3 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.